The Commissioner of the Food and Drug Administration should clearly communicate how the agency will use adverse event data from expanded access use when reviewing drugs and biologics for approval and marketing in the United States.
Burgess discusses the importance of FDA communication regarding drug approval processes.
Share
More from Michael Burgess
I thank the gentleman for yielding additional time. However, one-sided pressure by the White House is not the way to ensure that end. Mr. Speaker, I urge passage of this rule from our committee, and I urge passage of the underlying…
It is now my great privilege and high honor to yield 3 minutes to the gentleman from Texas (Mr. Arrington), the chairman of the Budget Committee, as we debate the first bipartisan budget bill to pass the floor of the House I think in the…
I am pleased to yield 4 minutes to the gentleman from Missouri (Mr. Alford) for his comments.
I urge all my fellow colleagues to join me in supporting H.R. 766 and ensuring that we continue to prioritize preventive healthcare initiatives for the betterment of all Americans, and I reserve the balance of my time.
Other voices in this conversation
